Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Pirker

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Journal of the National Cancer Institute|May 15, 1991
MDR1 gene expression and treatment outcome in acute myeloid leukemiaR Pirker, J Wallner, K Geissler, et al.
European Journal of Cancer (Oxford, England : 1990)|February 19, 1999
Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trialG Krajnik, W Wein, R Greil, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2010
ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapyB Besse, C Massard, V Haddad, et al.
Journal of the National Cancer Institute|January 18, 1989
Expression of a multidrug resistance gene in human cancersL J Goldstein, H Galski, A Fojo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 1999
Expression of the lung resistance protein predicts poor outcome in patients with multiple myelomaM Filipits, J Drach, G Pohl, et al.
Wiener Klinische Wochenschrift|October 23, 1997
Phase II trial of gemcitabine in advanced non-small-cell lung cancerR Malayeri, E Ulsperger, G Baumgartner, et al.
Pneumologie (Stuttgart, Germany)|November 9, 2018
[Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example]F Griesinger, S Radke, A Lüers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2000
Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): an AASLC phase II trial. Austrian Association for the Study of Lung CancerG Krajnik, A Mohn-Staudner, J Thaler, et al.
Lung Cancer (Amsterdam, Netherlands)|January 8, 2004
Consensus: the follow-up of the treated patientM Saunders, J P Sculier, D Ball, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2002
Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trialR Rosell, U Gatzemeier, D C Betticher, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Journal of the National Cancer Institute|May 15, 1991
MDR1 gene expression and treatment outcome in acute myeloid leukemiaR Pirker, J Wallner, K Geissler, et al.
European Journal of Cancer (Oxford, England : 1990)|February 19, 1999
Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trialG Krajnik, W Wein, R Greil, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2010
ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapyB Besse, C Massard, V Haddad, et al.
Journal of the National Cancer Institute|January 18, 1989
Expression of a multidrug resistance gene in human cancersL J Goldstein, H Galski, A Fojo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 1999
Expression of the lung resistance protein predicts poor outcome in patients with multiple myelomaM Filipits, J Drach, G Pohl, et al.
Wiener Klinische Wochenschrift|October 23, 1997
Phase II trial of gemcitabine in advanced non-small-cell lung cancerR Malayeri, E Ulsperger, G Baumgartner, et al.
Pneumologie (Stuttgart, Germany)|November 9, 2018
[Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example]F Griesinger, S Radke, A Lüers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2000
Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): an AASLC phase II trial. Austrian Association for the Study of Lung CancerG Krajnik, A Mohn-Staudner, J Thaler, et al.
Lung Cancer (Amsterdam, Netherlands)|January 8, 2004
Consensus: the follow-up of the treated patientM Saunders, J P Sculier, D Ball, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2002
Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trialR Rosell, U Gatzemeier, D C Betticher, et al.
Pageof 8